Drug Profile


Alternative Names: CR 1505; Loside; Loxizin

Latest Information Update: 20 Feb 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rottapharm
  • Developer Kaken Pharmaceutical; Rottapharm
  • Class Anti-inflammatories; Antineoplastics; Basic amino acids; Gastrokinetics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Cholecystokinin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Biliary pain; Pancreatic cancer
  • Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia; Pancreatitis

Most Recent Events

  • 20 Feb 2006 No development reported - Clinical-Phase-Unknown for Biliary pain in Italy (unspecified route)
  • 06 Nov 2003 Discontinued - Clinical-Phase-Unknown for Biliary pain in Italy (unspecified route)
  • 06 Nov 2003 Discontinued - Phase-II for Irritable bowel syndrome in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top